All deals
You are viewing a shared deal. With a free account you access the full showcase and talk directly with whoever manages the deal.
Biohax — "Epigenetics-Driven Personalized Nutrition Platform"
Capital Raising Live

Biohax — "Epigenetics-Driven Personalized Nutrition Platform"

10M
Raising target
United States
United States
Startup
10MRaising target
SeedRound stage
AnyMinimum ticket
LiveStatus

Who they are & what they do

SectorHealthcare
Industries
Life Sciences Tools & ServicesPersonalized Nutrition & SupplementsDtc And B2B HealthtechMedtech
Company overview

Biohax is building a personalized nutrition platform grounded in epigenetics — using DNA methylation patterns read from an at-home blood spot test to generate Epigenetic Biomarker Proxies (EBPs), which the company positions as more stable, longer-window indicators of health status than traditional single-point blood biomarkers. Rather than offering standardized supplements, Biohax's Tailored Script® platform combines up to 150+ ingredients into a single custom daily formulation per user, updated as retesting reveals changes in biomarker status — addressing what the company frames as a structural mismatch in the existing supplement industry, where most users take multiple undifferentiated products daily despite highly individual nutritional needs.

Commercially, the company is pursuing a phased distribution strategy rather than a traditional direct-to-consumer launch: Phase 1 (January 2026) targets B2B channels through five signed clinical partnerships and a 40,000+ cash-pay healthcare provider network inherited from the founder's prior ventures, designed to generate cash flow immediately without DTC customer-acquisition spend. Phase 2 (May 2026) extends into pharmacy integration, deploying a second production unit inside Strive Pharmacy (Phoenix, AZ) to add pharmaceutical categories — including GLP-1 medications, addressing a cited $71.7B US market — alongside the core supplement offering, with an exclusive channel relationship referenced with HIMS.

Key clients & traction

LifeSpanSupraHumanHone HealthHIMSStrive Pharmacy
Company type Startup
Country United States

Website: Confidential

Why look at this deal

Highlights

  1. 01Founder-backed, self-funded to-date
  2. 02Phased B2B-first distribution
  3. 03Committed clinical partner volume
  4. 04Proprietary custom formulation platform
  5. 05Pharma category expansion planned

Deal snapshot

Raising target10M
Round stageSeed
InstrumentSAFE
Minimum ticketAny
Pre-money valuation88M
Equity offering≈ 10.2% (post-money)

Locked fields are disclosed after expressing interest.

Data room

Public files are open to everyone. The rest unlock once you qualify.

For companies and advisors

Have a deal to bring to market?

Publish your deal on UCapital Dealflow and reach qualified buyers and investors. Data room, NDA and lead management included.

Disclaimer

UCapital Asset Management LLP is authorised and regulated by the Financial Conduct Authority (FCA) in the United Kingdom and by CONSOB in Italy, and operates in the United States through FINRA-licensed US partners and affiliates.

This platform serves informational and technological purposes only: it executes no market transactions, does not constitute a solicitation to invest and provides no financial advice of any kind. The platform lets users manage a deal through the technological tools made available to them, such as the CRM for lead tracking and analytics. No capital raising and no sale is executed on or through the platform: each individual deal is executed offline by the designated regulated entities, in accordance with the regulations in force in each country, their compliance frameworks and under their full responsibility.

The content is intended exclusively for eligible counterparties, professional investors and professional clients as defined by applicable regulations, and does not constitute a public offer. The information is not directed at persons in jurisdictions where its distribution or use would be contrary to local laws or regulations.

The data shown on these pages is public data or data collected and processed by UCapital. For user-created deals, the data is entered by the users themselves, who take full responsibility for what is published: the publication of a deal on the platform does not constitute a recommendation, endorsement or verification by UCapital.

The data shown may not always be real-time and may differ from what is verified in due diligence when contacting the regulated entities responsible for managing the deal. Any prices, valuations and projections are purely indicative.

Every investment carries risks, including the total loss of the capital invested. Past performance is not indicative of future results. Before any decision, investors must carry out their own assessments and consult the regulated entities managing the deal and, where appropriate, their own legal, tax and financial advisers.